Mark Dowling

Important work regarding high prevalence of BCMA expression in PBL. There is no consensus in the treatment of RR PBL and anti BCMA therapies are intriguing. Interestingly the two patients exposed to CD19 directed CART in this small series died. #lymsm

#CART and fixed #ibrutinib for #Mantle cell #lymphoma in @bloodjournal. More evidence that immunotherapy may help with high-risk molecular subtypes. Congrats to @adrianminson for driving this lightning-fast @petermacres IIT as part of his PHD! #lymsm bit.ly/3Q73904

Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations | Blood | American Society of Hematology ashpublications.org/blood/article/…

Late breaking at #ASCO23: In the phase 3 ZUMA-7 trial, patients with relapsed or refractory large B-cell lymphoma who received axi-cel (CD19-specific CAR T cells) had a 27.4% lower risk of death than patients who received standard therapy. Full trial results:

Zuma7 shows that, in spite of cross over in >50%, there is an OVERALL SURVIVAL BENEFIT for CAR-T (Axi-Cel) versus chemo+transplant for #DLBCL #lymphoma - the NEJM Paper is online! bit.ly/43Fpxmn #lymsm Great to have been a part of this practice-changing trial.

Surprised this went through peer-review unnoticed... What is the issue with the proposed analysis shown in the plot? Very exciting data nonetheless! ncbi.nlm.nih.gov/pmc/articles/P… @JCO_ASCO

Each year we join forces with @LLSusa & @SnowdomeAU to identify & fund new translational research projects. Congratulations Assoc. Professor Jane Oliaro @PeterMacRes and Professor Richard Lock @KidsCancerInst! Learn more: rebrand.ly/translational-…

A welcome investment in medical technology - cell and gene therapy research and therapy. nsw.gov.au/media-releases… @WestSydHealth @WestmeadInst @NSWHealth

Physics Quiz! How many Hiroshimas/Megatons of explosive force does it take to get the Tennis off the front page of all major Australian news outlets? (Clue: it's more than 1000 Hiroshimas)

@StephenORahilly “Exponential” means increasing by a constant percentage per unit time, not just “big”

Just need to get two pet peeves off my chest as I see them increasingly used in scientific writing. 1 Unique means one of a kind. “Very unique” is therefore meaningless. 2. “Disinterested” and “uninterested” are not synonymous. “Disinterested” means impartial/unbiased.That’s it!

Dan Suan - Omicron warning youtu.be/daskJMeud8A via @YouTube

Bishop - Belinda - Tisa-cel v SOC in 2L Agg NHL - Refract or < 12mo 1L, bridging OK - 1 EP: EFS - death or PD/SD at 12 week assessment - 322 random, 33% SOC had ASCT - Median EFS both arms 3mo - 51% crossed to tisa-cel tisa-cel < liso/Axi - or study design issue? #ASH21 #lymsm

POLARIX PFS subgroup analysis in supplementary of @NEJM Well worth a look! IPI 3-5 vs IPI 2 differences fairly striking. #ASH21 #lymsm #DLBCL

A fantastic opportunity to join our group @fredhutch @EvNewell1 as a Bioinformatics Analyst. social.icims.com/viewjob/pt1639… You will help us analyze high-dimensional proteomic/genomic data from CAR T cell patients (amongst other things!) Please RT! @xanhira @KrishnaRJuluri

@drjgauthier @rstatstweet Please tell me! And share your code 🤣

I'd be ashamed to tell you how long it took me to code this pseudo-swimmer plot in ggplot... #RStats @rstatstweet

Great review work carried out by Dr. @Razan_Mohty! 👍

Statement on the Doherty Institute modelling: The Doherty Institute understands how extremely challenging lockdown restrictions are for everyone.

@JoshCasan @Farehlab Nice work team!

Thrilled to see our group’s paper out. rdcu.be/cogHo Amongst the first demonstrating the potential for CRISPR-Cas13-based targeting of live SARS-CoV-2. Special congrats to the brilliant @Farehlab. Lucky to be part of this project as my first venture into basic science.

#ZUMA7 Is positive in favour of #CART #yescarta versus transplant in first high risk relapse of #DLBCL #lymphoma #lymsm. Incredibly exciting news and some actual numbers in the press release! Very exciting. businesswire.com/news/home/2021…